Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Faith E. Davies; Charlotte Pawlyn; Saad Z. Usmani; Jesus F. San-Miguel; Hermann Einsele; Eileen M. Boyle; Jill Corre; Daniel Auclair; Hearn Jay Cho; Sagar Lonial; Pieter Sonneveld; A. Keith Stewart; P. Leif Bergsagel; Martin F. Kaiser; Katja Weisel; Jonathan J. Keats; Joseph R. Mikhael; Kathryn E. Morgan; Irene M. Ghobrial; Robert Z. Orlowski; C. Ola Landgren; Francesca Gay; Joseph Caers; Wee Joo Chng; Ajai Chari; Brian A. Walker; Shaji K. Kumar; Luciano J. Costa; Kenneth C. Anderson; Gareth J. Morgan

doi:10.1158/2643-3230.BCD-21-0205

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Faith E. Davies^*
, Charlotte Pawlyn
, Saad Z. Usmani
, Jesus F. San-Miguel
, Hermann Einsele
, Eileen M. Boyle
, Jill Corre
, Daniel Auclair
, Hearn Jay Cho
, Sagar Lonial
, Pieter Sonneveld
, A. Keith Stewart
, P. Leif Bergsagel
, Martin F. Kaiser
, Katja Weisel
, Jonathan J. Keats
, Joseph R. Mikhael
, Kathryn E. Morgan
, Irene M. Ghobrial
, Robert Z. Orlowski

C. Ola Landgren, Francesca Gay, Joseph Caers, Wee Joo Chng, Ajai Chari, Brian A. Walker, Shaji K. Kumar, Luciano J. Costa, Kenneth C. Anderson, Gareth J. Morgan

^*Corresponding author for this work

Hematology

NYU Langone Health
Institute of Cancer Research (ICR), London
Royal Marsden Hospital, London
Memorial Sloan-Kettering Cancer Center
University of Navarra
University Hospital Würzburg
Institut national de la santé et de la recherche médicale
Multiple Myeloma Research Foundation
Icahn School of Medicine at Mount Sinai
Emory University
University Health Network
Mayo Clinic, Scottsdale, AZ
University Medical Center Hamburg-Eppendorf
Myeloma Patients Europe
University of Texas MD Anderson Cancer Center
University of Miami
University of Turin
CHU and University of Liège
Mayo Clinic Rochester, MN
University of Alabama at Birmingham
Perlmutter Cancer Center (Long Island)
Dana-Farber Cancer Institute
Indiana University
City of Hope Cancer Center (Phoenix)
Translational Genomics Research Institute
Princess Margaret Hospital Cancer Centre
Unité de Génomique du Myélome

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

93 Downloads (Pure)

Abstract

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Original language	English
Pages (from-to)	273-284
Number of pages	12
Journal	Blood cancer discovery
Volume	3
Issue number	7
DOIs	https://doi.org/10.1158/2643-3230.BCD-21-0205
Publication status	Published - 1 Jul 2022

Bibliographical note

Access to Document

10.1158/2643-3230.BCD-21-0205Licence: CC BY-ND

Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFinal published version, 4.84 MBLicence: CC BY-NC-ND

Cite this

Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., ... Morgan, G. J. (2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery, 3(7), 273-284. https://doi.org/10.1158/2643-3230.BCD-21-0205

@article{547d9aadac744c88b5e057d7d25ee744,

title = "Perspectives on the Risk-Stratified Treatment of Multiple Myeloma",

abstract = "The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.",

author = "Davies, \{Faith E.\} and Charlotte Pawlyn and Usmani, \{Saad Z.\} and San-Miguel, \{Jesus F.\} and Hermann Einsele and Boyle, \{Eileen M.\} and Jill Corre and Daniel Auclair and Cho, \{Hearn Jay\} and Sagar Lonial and Pieter Sonneveld and Stewart, \{A. Keith\} and Bergsagel, \{P. Leif\} and Kaiser, \{Martin F.\} and Katja Weisel and Keats, \{Jonathan J.\} and Mikhael, \{Joseph R.\} and Morgan, \{Kathryn E.\} and Ghobrial, \{Irene M.\} and Orlowski, \{Robert Z.\} and Landgren, \{C. Ola\} and Francesca Gay and Joseph Caers and Chng, \{Wee Joo\} and Ajai Chari and Walker, \{Brian A.\} and Kumar, \{Shaji K.\} and Costa, \{Luciano J.\} and Anderson, \{Kenneth C.\} and Morgan, \{Gareth J.\}",

note = "Publisher Copyright: {\textcopyright}2022 The Authors; Published by the American Association for Cancer Research.",

year = "2022",

month = jul,

day = "1",

doi = "10.1158/2643-3230.BCD-21-0205",

language = "English",

volume = "3",

pages = "273--284",

journal = "Blood cancer discovery",

issn = "2643-3230",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

Davies, FE, Pawlyn, C, Usmani, SZ, San-Miguel, JF, Einsele, H, Boyle, EM, Corre, J, Auclair, D, Cho, HJ, Lonial, S, Sonneveld, P, Stewart, AK, Bergsagel, PL, Kaiser, MF, Weisel, K, Keats, JJ, Mikhael, JR, Morgan, KE, Ghobrial, IM, Orlowski, RZ, Landgren, CO, Gay, F, Caers, J, Chng, WJ, Chari, A, Walker, BA, Kumar, SK, Costa, LJ, Anderson, KC & Morgan, GJ 2022, 'Perspectives on the Risk-Stratified Treatment of Multiple Myeloma', Blood cancer discovery, vol. 3, no. 7, pp. 273-284. https://doi.org/10.1158/2643-3230.BCD-21-0205

TY - JOUR

T1 - Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

AU - Davies, Faith E.

AU - Pawlyn, Charlotte

AU - Usmani, Saad Z.

AU - San-Miguel, Jesus F.

AU - Einsele, Hermann

AU - Boyle, Eileen M.

AU - Corre, Jill

AU - Auclair, Daniel

AU - Cho, Hearn Jay

AU - Lonial, Sagar

AU - Sonneveld, Pieter

AU - Stewart, A. Keith

AU - Bergsagel, P. Leif

AU - Kaiser, Martin F.

AU - Weisel, Katja

AU - Keats, Jonathan J.

AU - Mikhael, Joseph R.

AU - Morgan, Kathryn E.

AU - Ghobrial, Irene M.

AU - Orlowski, Robert Z.

AU - Landgren, C. Ola

AU - Gay, Francesca

AU - Caers, Joseph

AU - Chng, Wee Joo

AU - Chari, Ajai

AU - Walker, Brian A.

AU - Kumar, Shaji K.

AU - Costa, Luciano J.

AU - Anderson, Kenneth C.

AU - Morgan, Gareth J.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

AB - The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

UR - https://www.scopus.com/pages/publications/85137812437

U2 - 10.1158/2643-3230.BCD-21-0205

DO - 10.1158/2643-3230.BCD-21-0205

M3 - Article

C2 - 35653112

AN - SCOPUS:85137812437

SN - 2643-3230

VL - 3

SP - 273

EP - 284

JO - Blood cancer discovery

JF - Blood cancer discovery

IS - 7

ER -

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this